Eva Carrasco

5.8k total citations
77 papers, 2.0k citations indexed

About

Eva Carrasco is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eva Carrasco has authored 77 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 43 papers in Cancer Research and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eva Carrasco's work include Cancer Treatment and Pharmacology (40 papers), Breast Cancer Treatment Studies (40 papers) and Advanced Breast Cancer Therapies (29 papers). Eva Carrasco is often cited by papers focused on Cancer Treatment and Pharmacology (40 papers), Breast Cancer Treatment Studies (40 papers) and Advanced Breast Cancer Therapies (29 papers). Eva Carrasco collaborates with scholars based in Spain, United States and Italy. Eva Carrasco's co-authors include Miguel Martín, Rosalía Caballero, Lourdes Calvo, José Luis Perez‐Gracia, Philip S. Bernard, Aňa Lluch, Charles M. Perou, Aleix Prat, Maggie C.U. Cheang and Scott Tyldesley and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Eva Carrasco

74 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Carrasco Spain 22 1.5k 1.1k 476 358 302 77 2.0k
Silvia Dellapasqua Italy 25 1.1k 0.8× 1.1k 0.9× 329 0.7× 458 1.3× 217 0.7× 55 1.8k
Kristi McIntyre United States 16 1.6k 1.1× 959 0.8× 405 0.9× 328 0.9× 229 0.8× 39 1.9k
Giuseppe Cancello Italy 24 1.5k 1.0× 1.1k 1.0× 435 0.9× 316 0.9× 247 0.8× 44 2.0k
P. Kelly Marcom United States 20 1.1k 0.8× 669 0.6× 304 0.6× 378 1.1× 334 1.1× 49 1.8k
Amy P. Sing United States 16 1.4k 0.9× 745 0.7× 435 0.9× 500 1.4× 122 0.4× 32 1.9k
Stephen P. Anthony United States 14 881 0.6× 603 0.5× 368 0.8× 482 1.3× 103 0.3× 53 1.5k
Holm Eggemann Germany 22 694 0.5× 651 0.6× 238 0.5× 231 0.6× 382 1.3× 76 1.6k
Federico Piacentini Italy 23 1.3k 0.9× 718 0.6× 517 1.1× 386 1.1× 124 0.4× 115 1.9k
Shannon McKernin United States 7 931 0.6× 817 0.7× 348 0.7× 211 0.6× 179 0.6× 7 1.4k
S M Edgerton United States 13 1.1k 0.8× 661 0.6× 199 0.4× 748 2.1× 216 0.7× 14 1.7k

Countries citing papers authored by Eva Carrasco

Since Specialization
Citations

This map shows the geographic impact of Eva Carrasco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Carrasco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Carrasco more than expected).

Fields of papers citing papers by Eva Carrasco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Carrasco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Carrasco. The network helps show where Eva Carrasco may publish in the future.

Co-authorship network of co-authors of Eva Carrasco

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Carrasco. A scholar is included among the top collaborators of Eva Carrasco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Carrasco. Eva Carrasco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Reilly, Séamus, Inês Vaz-Luís, Virginie Adam, et al.. (2025). Advancing equitable access to innovation in breast cancer. npj Breast Cancer. 11(1). 71–71. 1 indexed citations
2.
3.
Ciruelos, Eva, Álvaro Montaño, César A. Rodríguez, et al.. (2020). Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07). European Journal of Cancer Care. 29(4). e13253–e13253. 7 indexed citations
4.
Ocaña, Alberto, Marta Gil-Martín, Silvia Antolín, et al.. (2019). Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. Breast Cancer Research and Treatment. 174(3). 693–701. 36 indexed citations
5.
Borrego, Manuel Ruíz, Marta Gil-Martín, Silvia Antolín, et al.. (2017). A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04. Annals of Oncology. 28. v75–v75. 1 indexed citations
6.
Negrouk, Anastassia, Denis Lacombe, Fátima Cardoso, et al.. (2017). Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. ESMO Open. 2(3). e000187–e000187. 9 indexed citations
7.
8.
Martín, Miguel, Manuel Ruíz‐Borrego, José M. Pérez, et al.. (2016). A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study). Annals of Oncology. 27. vi87–vi87. 3 indexed citations
9.
Santonja, Ángela, Joan Albanell, Alfonso Sánchez‐Muñoz, et al.. (2016). Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer. Annals of Oncology. 27. vi55–vi55.
10.
Martín, Miguel, Moshe Inbar, Eva Carrasco, et al.. (2015). Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006). Journal of Clinical Oncology. 1 indexed citations
11.
Martín, Miguel, Jan C. Brase, Lourdes Calvo, et al.. (2014). Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Research. 16(2). R38–R38. 107 indexed citations
12.
Alba, Emilio, Joan Albanell, Juan de la Haba-Rodríguez, et al.. (2014). Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. British Journal of Cancer. 110(5). 1139–1147. 55 indexed citations
13.
Alba, Emilio, Lourdes Calvo, Joan Albanell, et al.. (2012). Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Annals of Oncology. 23(12). 3069–3074. 147 indexed citations
14.
Martín, Miguel, Pedro Sánchez‐Rovira, Montserrat Muñoz-Mateu, et al.. (2011). Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study. Annals of Oncology. 22(12). 2591–2596. 26 indexed citations
15.
Sánchez‐Muñoz, Alfonso, Eva Carrasco, Ana Laura Ortega Granados, et al.. (2010). Is it Possible to Increase pCR in the Neoadjuvant Treatment With a Dose-Dense/Sequential Combination?. American Journal of Clinical Oncology. 33(5). 432–437. 12 indexed citations
16.
17.
Llombart‐Cussac, Antonio, Sonia Del Barco Berrón, Gopinath Ganji, et al.. (2009). Abstract #LB-256: Enzastaurin inhibits in vivo GSK3\#946; phosphorylation in early breast cancer. Cancer Research. 69. 2 indexed citations
18.
19.
Perez‐Gracia, José Luis, María del Mar Muñoz, Grant Williams, et al.. (2005). Assessment of the value of confirming responses in clinical trials in oncology. European Journal of Cancer. 41(11). 1528–1532. 7 indexed citations
20.
Baselga, José, Antonio Llombart‐Cussac, Meritxell Bellet, et al.. (2003). Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Annals of Oncology. 14(9). 1383–1390. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Silvia Dellapasqua Breakdown of academic impact, for papers by Kristi McIntyre Breakdown of academic impact, for papers by Giuseppe Cancello Breakdown of academic impact, for papers by P. Kelly Marcom Breakdown of academic impact, for papers by Amy P. Sing Breakdown of academic impact, for papers by Stephen P. Anthony Breakdown of academic impact, for papers by Holm Eggemann Breakdown of academic impact, for papers by Federico Piacentini Breakdown of academic impact, for papers by Shannon McKernin Breakdown of academic impact, for papers by S M Edgerton
Rankless by CCL
2026